Angiotensin-converting enzyme inhibitors for stroke prevention: Is there HOPE for PROGRESS after LIFE?

Stroke

Volumn 34, Issue 2, 2003, Pages 354-356

  Hankey, Graeme J ^a,b  

^a ROYAL PERTH HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Angiotensin converting enzyme inhibitors; Angiotensin II; Risk factors; Stroke prevention

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANGIOTENSIN; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CANDESARTAN HEXETIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INDAPAMIDE; LOSARTAN; NONSTEROID ANTIINFLAMMATORY AGENT; PERINDOPRIL; RAMIPRIL; TELMISARTAN; VALSARTAN;

ANGIONEUROTIC EDEMA; BLOOD PRESSURE; CLINICAL TRIAL; COUGHING; DRUG MECHANISM; HUMAN; HYPERTENSION; HYPONATREMIA; KIDNEY DISEASE; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; PROPHYLAXIS; RISK FACTOR; SHORT SURVEY; STROKE;

ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIALS; DIURETICS; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; LIFE STYLE; PRACTICE GUIDELINES; RAMIPRIL; RECEPTORS, ANGIOTENSIN; RISK; RISK FACTORS;

EID: 0037321345     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000054261.97525.4B     Document Type: Short Survey

References (19)

1. Blood Pressure Lowering Treatment Trialists' Collaboration. Effect of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials, Lancet. 2000;355:1955-1964.
2. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145-153.
3. Bosch J, Yusuf S, Pogue J, Sleight P, Lonn E, Rangoonwala B, Davies R, Ostergren J, Probstfield J on behalf of the HOPE Investigators. Use of ramipril in preventing stroke: double-blind randomised trial. BMJ. 2002; 324:1-5.
4. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001; 358:1033-1041.
5. Brunner HR, Laragh JH, Baer L, Newton MA, Goodwin FT, Krakoff LR, Bard RH, Buhler FR. Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med. 1972;286:441-449.
6. Sleight P, Yusuf S, Pogue J, Tsuyuki R, Diaz R, Probstfield J, for the Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Blood-pressure reduction and cardiovascular risk in HOPE study. Lancet. 2001:358:2130-2131.
7. Svensson P, de Faire U, Sleight P, Yusuf S, Östergren J. Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE substudy. Hypertension. 2001;38:e28-e32.
8. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U, Fyhrquist F, Ibesen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminem MS, Omivak P, Oparil S, Wedel H for the LIFE study group. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.
9. Hansson L, Lithell H, Skoog I, et al. The Study of COgnition and Prognosis in the Elderly (SCOPE). Presented at the International Hypertension Society/European Hypertension Society Meeting. June 27, 2002, Prague, Czech Republic.
10. Weber KT. Aldosterone in congestive heart failure. N Engl J Med. 2001;345:1689-1697.
11. Lonn EM, Yusuf S, Jha P, Montague TH, Teo KK, Benedict CR, Pitt B. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation. 1994;90:2056-2069.
12. Cohn JN. ACE inhibition and vascular remodeling of resistance vessels: vascular compliance and cardiovascular implications. Heart Dis. 2000;2: S2-S6.
13. Schwartz Kopff B, Beh M, Mundhenke M, Strauer BE. Repair of coronary arterioles after treatment with perindopril in hypertensive heart disease. Hypertension. 2000;36:220-225.
14. Farmer JA, Torre-Amione G. The renin angiotensin system as a risk factor for coronary artery disease. Curr Atheroscler Rep. 2001;3: 117-124.
15. Teo KK, Yusuf S, Pfeffer M, Kober L, Hall A, Pogue J, Latini R, Collins R, for the ACE Inhibitors Collaborative Group. Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review. Lancet. 2002; 360:1037-1043.
16. Mackenzie IS, Brown MJ. Genetic profiling versus drug rotation in the optimisation of antihypertensive treatment Clin Med JRCPL. 2002;2: 465-473.
17. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger GH, Neaton J, Sharma D. Thiyagarajan B. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial. The Losartan Heart Failure Survival Study ELITE II. Lancet. 2000:355:1582-1587.
18. Lewis EJ, Hunsicker LG. Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R. Raz I. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:51-60.
19. Brenner BM, Cooper ME, De Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.